Suppr超能文献

ISG15是骨肉瘤的一个潜在治疗靶点:基于生物信息学和体外实验的综合分析

ISG15 is a potential therapeutic target for osteosarcoma: a comprehensive analysis based on bioinformatics and in vitro experiments.

作者信息

Liao Yedan, Zhang Xueqi, Tang Jiadai, Hu Fengdi, Li Dongqi, Song Hongli, Chen Jiaojiao, Guo Jiangyan, Li Rong, Lin Yanping, Xie Lin

机构信息

Department of Gastrointestinal Oncology, The Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center) Kunming, Yunnan, China.

Graduate School, Kunming Medical University Kunming, Yunnan, China.

出版信息

Am J Transl Res. 2023 Feb 15;15(2):817-833. eCollection 2023.

Abstract

BACKGROUND

The expression of aberrant interferon-stimulated gene 15 (ISG15) is connected with various human diseases, including cancer. ISG15 is involved in tumor formation and metastasis. However, its role in osteosarcoma is uncertain.

METHODS

ISG15 expression in pan-cancer from RNA Sequencing data were obtained from The Cancer Genome Atlas (TCGA) and Genotype Tissue Expression (GTEx) databases. The relationship between ISG15 expression and prognosis was assessed through TCGA clinical survival data. Immunohistochemistry (IHC) images of ISG15 were retrieved using the Human Protein Atlas to analyze the differences in selected normal and tumor tissues. Gene enrichment analysis and signaling pathway analysis were used to assess the potential role of ISG15 in sarcoma, and the correlation between ISG15 expressions and immune cell infiltration levels was estimated by immune infiltration analysis. The expression levels of ISG15 were assessed by qRT-PCR and IHC. Colony formation, wound healing assay and transwell assay were used to detect the effects of ISG15 on the biological behaviors of osteosarcoma cells. The correlation between ISG15 levels and CD8+/CD68+ cells was further examined by double-labeled immunofluorescence. The chemotactic effect of ISG15 on CD8+/CD68+ cells was demonstrated by chemotactic experiments and flow cytometry.

RESULTS

ISG15 was highly expressed in most cancers, while high ISG15 expression was significantly correlated with poor overall survival. Gene enrichment analysis in sarcoma suggested that antigen processing and presentation might be involved in the oncogenic mechanism of ISG15. Further immune infiltration analysis showed that high ISG15 expression might reflect the infiltration level of certain immune cells. Additionally, our verification showed that ISG15 was significantly related to the occurrence and metastasis of osteosarcoma, and knockdown of ISG15 significantly altered cell biological behavior, resulting in decreased proliferation, migration and invasion capabilities of osteosarcoma cells. The high expression of ISG15 in osteosarcoma tissue was associated with a high level of CD68+ immune cell infiltration while a low level of CD8+ T cell infiltration. CD68+ immune cells were recruited in vitro by overexpression of ISG15, which on the contrary could weaken the chemotaxis of CD8+ T cells.

CONCLUSION

High ISG15 expression is an inherent feature of osteosarcoma and triggers tumorigenesis and metastasis by regulating tumor immunogenicity. ISG15 is expected to be the target of osteosarcoma treatment.

摘要

背景

异常干扰素刺激基因15(ISG15)的表达与包括癌症在内的多种人类疾病相关。ISG15参与肿瘤形成和转移。然而,其在骨肉瘤中的作用尚不确定。

方法

从癌症基因组图谱(TCGA)和基因型组织表达(GTEx)数据库中获取RNA测序数据中泛癌的ISG15表达。通过TCGA临床生存数据评估ISG15表达与预后的关系。使用人类蛋白质图谱检索ISG15的免疫组织化学(IHC)图像,以分析选定的正常组织和肿瘤组织中的差异。基因富集分析和信号通路分析用于评估ISG15在肉瘤中的潜在作用,免疫浸润分析估计ISG15表达与免疫细胞浸润水平之间的相关性。通过qRT-PCR和IHC评估ISG15的表达水平。采用集落形成、伤口愈合试验和Transwell试验检测ISG15对骨肉瘤细胞生物学行为的影响。通过双标免疫荧光进一步检测ISG15水平与CD8+/CD68+细胞之间的相关性。趋化实验和流式细胞术证明ISG15对CD8+/CD68+细胞的趋化作用。

结果

ISG15在大多数癌症中高表达,而高ISG15表达与较差的总生存期显著相关。肉瘤中的基因富集分析表明,抗原加工和呈递可能参与ISG15的致癌机制。进一步的免疫浸润分析表明,高ISG15表达可能反映某些免疫细胞的浸润水平。此外,我们的验证表明,ISG15与骨肉瘤的发生和转移显著相关,敲低ISG15显著改变细胞生物学行为,导致骨肉瘤细胞的增殖、迁移和侵袭能力下降。骨肉瘤组织中ISG15的高表达与高水平的CD68+免疫细胞浸润和低水平的CD8+T细胞浸润相关。体外通过ISG15过表达招募CD68+免疫细胞,相反,这可能削弱CD8+T细胞的趋化作用。

结论

高ISG15表达是骨肉瘤的固有特征,通过调节肿瘤免疫原性触发肿瘤发生和转移。ISG15有望成为骨肉瘤治疗的靶点。

相似文献

本文引用的文献

9
Downregulation of serum miR-194 predicts poor prognosis in osteosarcoma patients.血清 miR-194 下调预示着骨肉瘤患者预后不良。
Ann Diagn Pathol. 2020 Jun;46:151488. doi: 10.1016/j.anndiagpath.2020.151488. Epub 2020 Mar 3.
10

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验